Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

728 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
Kobayashi K, Matsuyama H, Kawai T, Ikeda A, Miyake M, Nishimoto K, Matsushita Y, Komura K, Abe T, Kume H, Nishiyama H, Fujimoto K, Oyama M, Miyake H, Inoue K, Mitsui T, Kawakita M, Ohyama C, Mizokami A, Kuroiwa H. Kobayashi K, et al. Among authors: oyama m. Int J Urol. 2022 Jul;29(7):632-638. doi: 10.1111/iju.14854. Epub 2022 Mar 15. Int J Urol. 2022. PMID: 35293022 Free PMC article.
The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: a multi-institutional study.
Tanaka N, Kikuchi E, Shirotake S, Kanao K, Matsumoto K, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Hayakawa N, Ito Y, Kosaka T, Kodaira K, Oyama M, Miyajima A, Momma T, Nakagawa K, Ueno M, Oya M. Tanaka N, et al. Among authors: oyama m. Eur Urol. 2014 Jan;65(1):227-34. doi: 10.1016/j.eururo.2012.11.050. Epub 2012 Dec 1. Eur Urol. 2014. PMID: 23219372
Independent predictors for bladder outcomes after treatment of intravesical recurrence following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma.
Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Hayakawa N, Hagiwara M, Kosaka T, Oyama M, Miyajima A, Momma T, Nakagawa K, Jinzaki M, Hasegawa S, Nakajima Y, Oya M. Tanaka N, et al. Among authors: oyama m. Ann Surg Oncol. 2014 Sep;21(9):3151-8. doi: 10.1245/s10434-014-3657-y. Epub 2014 Mar 29. Ann Surg Oncol. 2014. PMID: 24682698
Oral 5-aminolevulinic acid mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A randomized, double-blind, multicentre phase II/III study.
Inoue K, Anai S, Fujimoto K, Hirao Y, Furuse H, Kai F, Ozono S, Hara T, Matsuyama H, Oyama M, Ueno M, Fukuhara H, Narukawa M, Shuin T. Inoue K, et al. Among authors: oyama m. Photodiagnosis Photodyn Ther. 2015 Jun;12(2):193-200. doi: 10.1016/j.pdpdt.2015.03.008. Epub 2015 Apr 2. Photodiagnosis Photodyn Ther. 2015. PMID: 25843912 Clinical Trial.
The clinical trial on the safety and effectiveness of the photodynamic diagnosis of non-muscle-invasive bladder cancer using fluorescent light-guided cystoscopy after oral administration of 5-aminolevulinic acid (5-ALA).
Inoue K, Matsuyama H, Fujimoto K, Hirao Y, Watanabe H, Ozono S, Oyama M, Ueno M, Sugimura Y, Shiina H, Mimata H, Azuma H, Nagase Y, Matsubara A, Ito YM, Shuin T. Inoue K, et al. Among authors: oyama m. Photodiagnosis Photodyn Ther. 2016 Mar;13:91-96. doi: 10.1016/j.pdpdt.2015.12.011. Epub 2016 Jan 2. Photodiagnosis Photodyn Ther. 2016. PMID: 26751700 Clinical Trial.
Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial.
Oyama M, Sugiyama T, Nozawa M, Fujimoto K, Kishida T, Kimura G, Tokuda N, Hinotsu S, Shimozuma K, Akaza H, Ozono S. Oyama M, et al. Jpn J Clin Oncol. 2017 Jun 1;47(6):551-559. doi: 10.1093/jjco/hyw194. Jpn J Clin Oncol. 2017. PMID: 28334974 Free PMC article. Clinical Trial.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T; RANGE study investigators. Petrylak DP, et al. Lancet. 2017 Nov 18;390(10109):2266-2277. doi: 10.1016/S0140-6736(17)32365-6. Epub 2017 Sep 12. Lancet. 2017. PMID: 28916371 Clinical Trial.
728 results